Fig. 2
Adjuvant effect of SK-TCL (formulation) used with a DC vaccine, in 4 T1 tumor metastasis in mice. Test mice were injected subcutaneously with 4 T1-Luc2 cells (5 × 105 cells/100 μl PBS/mouse) into the mammary fat pad under isoflurane anesthesia. At 15 days post tumor cell implantation, primary tumors were surgically resected. Specifically formulated DC vaccines (1 × 106 DCs/200 μl PBS/mouse) were delivered via tail vain injection to mice at 0, 7 and 14 days post tumor resection. a Representative in vivo bioluminescent images of test mice (8 mice/group) treated with PBS, mDCs, mDCs + Naive-TCL, mDCs + SK-TCL and mDCs + Dox-TCL vaccines after resection of the 4 T1 orthotopic primary tumors. The red signals represent the highest level on the colorimetric scale. b Percentage of whole body (all organs) free from metastasis in mice (8 mice/group). The metastasis levels of tumors in test mice were scored within the indicated time course as revealed by bioluminescence imaging. c Survival rate of test mice after resection of 4 T1 tumors and treatment with the indicated DC vaccine regimes. Similar trends of results were obtained from four independent experiments